Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19


Cellular and Molecular Mechanisms of 3,3'-Diindolylmethane in Gastrointestinal Cancer.

Kim SM.

Int J Mol Sci. 2016 Jul 19;17(7). pii: E1155. doi: 10.3390/ijms17071155. Review.


Vimentin, colon cancer progression and resistance to butyrate and other HDACis.

Lazarova DL, Bordonaro M.

J Cell Mol Med. 2016 Jun;20(6):989-93. doi: 10.1111/jcmm.12850. Epub 2016 Apr 12. Review.


Consensus on the Prevention, Screening, Early Diagnosis and Treatment of Colorectal Tumors in China: Chinese Society of Gastroenterology, October 14-15, 2011, Shanghai, China.

Fang JY, Zheng S, Jiang B, Lai MD, Fang DC, Han Y, Sheng QJ, Li JN, Chen YX, Gao QY.

Gastrointest Tumors. 2014 Jun;1(2):53-75. doi: 10.1159/000362585. Epub 2014 May 9.


Sulindac, 3,3'-diindolylmethane and curcumin reduce carcinogenesis in the Pirc rat, an Apc-driven model of colon carcinogenesis.

Femia AP, Soares PV, Luceri C, Lodovici M, Giannini A, Caderni G.

BMC Cancer. 2015 Sep 3;15:611. doi: 10.1186/s12885-015-1627-9.


Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors.

Kim E, Bisson WH, Löhr CV, Williams DE, Ho E, Dashwood RH, Rajendran P.

Curr Top Med Chem. 2016;16(7):714-31. Review.


The role of dietary histone deacetylases (HDACs) inhibitors in health and disease.

Bassett SA, Barnett MP.

Nutrients. 2014 Oct 15;6(10):4273-301. doi: 10.3390/nu6104273. Review.


Mechanisms and therapeutic implications of cell death induction by indole compounds.

Ahmad A, Sakr WA, Rahman KW.

Cancers (Basel). 2011 Jul 19;3(3):2955-74. doi: 10.3390/cancers3032955.


Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET.

Kim SW, Hooker JM, Otto N, Win K, Muench L, Shea C, Carter P, King P, Reid AE, Volkow ND, Fowler JS.

Nucl Med Biol. 2013 Oct;40(7):912-8. doi: 10.1016/j.nucmedbio.2013.06.007. Epub 2013 Jul 29.


3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.

Beaver LM, Yu TW, Sokolowski EI, Williams DE, Dashwood RH, Ho E.

Toxicol Appl Pharmacol. 2012 Sep 15;263(3):345-51. doi: 10.1016/j.taap.2012.07.007. Epub 2012 Jul 16.


Diindolylmethane-mediated Gli1 protein suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo.

Kandala PK, Srivastava SK.

J Biol Chem. 2012 Aug 17;287(34):28745-54. doi: 10.1074/jbc.M112.351379. Epub 2012 Jul 6.


Epigenetics Offer New Horizons for Colorectal Cancer Prevention.

Schnekenburger M, Diederich M.

Curr Colorectal Cancer Rep. 2012 Mar;8(1):66-81. Epub 2012 Jan 14.


Dietary factors and epigenetic regulation for prostate cancer prevention.

Ho E, Beaver LM, Williams DE, Dashwood RH.

Adv Nutr. 2011 Nov;2(6):497-510. doi: 10.3945/an.111.001032. Epub 2011 Nov 3. Review.


Histone deacetylase modulators provided by Mother Nature.

Seidel C, Schnekenburger M, Dicato M, Diederich M.

Genes Nutr. 2012 Jul;7(3):357-67. doi: 10.1007/s12263-012-0283-9. Epub 2012 Feb 12.


Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells.

Rajendran P, Ho E, Williams DE, Dashwood RH.

Clin Epigenetics. 2011;3(1):4. doi: 10.1186/1868-7083-3-4. Epub 2011 Oct 26.


Gene therapy for C-26 colon cancer using heparin-polyethyleneimine nanoparticle-mediated survivin T34A.

Zhang L, Gao X, Men K, Wang B, Zhang S, Qiu J, Huang M, Gou M, Huang N, Qian Z, Zhao X, Wei Y.

Int J Nanomedicine. 2011;6:2419-27. doi: 10.2147/IJN.S23582. Epub 2011 Oct 19.


Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic.

Banerjee S, Kong D, Wang Z, Bao B, Hillman GG, Sarkar FH.

Mutat Res. 2011 Jul-Oct;728(1-2):47-66. doi: 10.1016/j.mrrev.2011.06.001. Epub 2011 Jun 15. Review.


Cancer chemoprevention by dietary polyphenols: promising role for epigenetics.

Link A, Balaguer F, Goel A.

Biochem Pharmacol. 2010 Dec 15;80(12):1771-92. doi: 10.1016/j.bcp.2010.06.036. Epub 2010 Jun 26. Review.


Activation of checkpoint kinase 2 by 3,3'-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells.

Kandala PK, Srivastava SK.

Mol Pharmacol. 2010 Aug;78(2):297-309. doi: 10.1124/mol.110.063750. Epub 2010 May 5.


Chemopreventive agent 3,3'-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases.

Li Y, Li X, Guo B.

Cancer Res. 2010 Jan 15;70(2):646-54. doi: 10.1158/0008-5472.CAN-09-1924. Epub 2010 Jan 12.

Supplemental Content

Support Center